The Academy of Immuno-Oncology recognizes individuals who have made seminal contributions that advance the field of cancer immunotherapy for the benefit of patients. Contributions from Academy members span basic discovery, translational research, clinical application, and impact on regulatory science and manufacturing, among other areas.
Annually, SITC conducts an open call for nominations and inducts a new class of Fellows into the Academy of Immuno-Oncology, one of the society’s most prestigious honors. (Actively serving nomination committee members or Board members are not eligible for nomination.) Fellows of the Academy of Immuno-Oncology bear the designation “FAIO.”